UNSPSC 51363505: Hyoscyamus/passion flower/phenobarbital/thiamine/valerian

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN301. This VA Drug Class (CN301) classifies this compound as belonging to the group BARBITURIC ACID DERIVATIVE SEDATIVES/HYPNOTICS.

UNSPSC 51363505 Hyoscyamus/passion flower/phenobarbital/thiamine/valerian is a Commodity code that shows a significant mismatch between its nominal pharmaceutical scope and recent state and local procurement activity. The single recent opportunity identified under this code—Seminole County, Florida's IFB60459723LAS posted on June 30, 2026—solicits naloxone and drug deactivation systems for community health initiatives, products unrelated to the botanical extracts and barbiturates named in the code itself. The actual procurement is for naloxone kits and safe drug deactivation equipment with quarterly delivery requirements, not the compounded or formulated products the code's name implies. This signals either a systematic mislabeling of the opportunity by the issuing body or minimal genuine activity under this particular code tier.

Seminole County, Florida represents the only identified recent issuing body under this code, with an IFB notice posted June 30, 2026 and a response deadline of July 26, 2023—a date inconsistency in the source itself that raises data-quality concerns. The solicitation calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must include shipping and delivery costs in proposals, maintain workers' compensation and commercial general liability insurance, pass E-Verify confirmation, and meet drug-free workplace certification requirements. The contract offers an initial two-year term with a one-year renewal option and was potentially funded through FEMA, introducing federal compliance obligations. Given the mismatch between the code's documented scope and the opportunity's actual procurement, this code appears inactive for its stated commodity class and unlikely to generate relevant pursuit activity without clearer pharmaceutical sourcing opportunities.